Continuous glucose monitors have become a fixture on millions of wrists and arms, but the technology remains stubbornly focused on a single molecule. Droplet Scientific, a University of Southampton spin-out, thinks it has a way to measure far more than blood sugar with the same portability and real-time feedback patients have come to expect from devices like Abbott's FreeStyle Libre.
The company has a £1.5 million equity round scheduled for September 2026, according to Funding Spotter, which tracks UK Companies House filings. Droplet Scientific declined to name investors, and formal allotment statements had not appeared in public records as of late September, though such filings often lag by weeks. The fundraise, roughly $1.9 million, arrives as the Southampton-based startup prepares to demonstrate what its founders describe as lab-grade accuracy in a palm-sized device.
Founded in September 2022, Droplet Scientific has built its platform around droplet microfluidics, a technique that performs traditional wet-chemistry assays in nanolitre-sized droplets. Each droplet acts as a miniature test tube, with inline optical sensors reading results every few seconds. The company claims the system can measure glucose, lactate, hormones like cortisol, and therapeutic drugs including lithium and propofol. It integrates with ultrafiltration, microdialysis, and microneedle sampling methods, depending on the application.
Professor Xize Niu, who leads the company while maintaining his position at the university, has refined the underlying technology over multiple years. His lab published a validation study in Nature Communications in 2019, demonstrating glucose and lactate monitoring via microdialysis in living tissue. A follow-up paper in Analyst in 2021 extended the platform to cortisol, signaling broader ambitions beyond metabolic markers.
Niu previously founded SouthWestSensor and has published over 100 peer-reviewed papers on microfluidics and lab-on-chip systems, according to his university profile. He has secured over £3 million in UK research grants and holds multiple patents in droplet microfluidics, including a 2019 US patent covering methods for droplet generation.
The company operates from the Catalyst accelerator at Southampton Science Park and employs between two and 10 people, according to LinkedIn. It relocated to the Science Park address in October 2025, corporate records show.
A Crowded but Narrow Market
The continuous monitoring space is not without incumbents. Abbott and Dexcom have effectively locked up the glucose market, with devices that have achieved mass adoption among diabetics. Nova Biomedical offers portable lactate meters for athletic training and clinical use, though these remain largely point-of-care rather than continuous.
For intensive care settings, M Dialysis markets the ISCUSflex analyzer, which uses microdialysis to track glucose, lactate, pyruvate, and other metabolites in real time. But continuous monitoring of biomarkers beyond these established categories remains largely experimental. Academic reviews from recent years describe microneedle-based platforms for continuous drug and metabolite tracking as promising but beset by translational hurdles, particularly around long-term sensor stability and regulatory pathways.
Droplet Scientific claims its lactate system covers the full physiological range up to 20 millimolar with a limit of detection of 0.16 millimolar, according to the company's website. Whether those specs translate to clinical utility in crowded hospital wards or home settings remains to be seen.
Next Steps, Quietly
The company had planned to exhibit at MEDICA, the German medical trade show, though it has not publicly disclosed clinical pilot sites or commercial customers. Southampton Science Park described Droplet Scientific as "transforming point-of-care diagnostics and precision medicine through ingenious wearable and portable technology" in a welcome post, the sort of language accelerators favor when a tenant shows promise.
Junda Niu holds between 25 and 50 percent ownership and voting rights, according to Companies House persons-with-significant-control records. The startup executed a share subdivision in May and filed governance resolutions through August, routine corporate housekeeping ahead of an equity round.
Droplet Scientific has the academic pedigree and the published validation data. What it doesn't yet have is evidence the technology can survive outside the controlled environment of a university lab, where interference from body chemistry, patient movement, and the messy realities of clinical workflows often trip up even the most elegant science.
